LARA - LAM Australasia Research Alliance. Seeking a cure for LAM (Lymphangioleiomyomatosis)

Contact Us

+61 (0) 419 185 491
+61 (0) 411 816 444

PO Box 636 Bondi Junction
NSW 1355 Australia

admin@lara.org.au

The LAM Australasia Research Alliance (LARA) is dedicated to improving the health prospects of women with LAM in Australia, New Zealand and throughout the region. A disease that affects only women, LAM is rare and often devastating.

ALL DONATIONS TO LARA ARE FULLY TAX DEDUCTIBLE

Your contribution to LARA will go 100% to funding vital medical research to find a cure for LAM.
You can donate to the LAM Australasia Research Alliance by sending us a cheque, using our PayPal facility, or by making a deposit directly to our ANZ Bank account: 012 055 4926 67193.
Please advise us of your donation by sending an email to admin@lara.org.au with your name, address and email address. We will respond with our thanks and a fully tax deductible receipt.

Major Donors
Macquarie Group Foundation
Roth Charitable Foundation
Mr Robert Gavshon
Hollick Wines

Acknowledgements
LARA thanks the professionals who work pro bono for this not-for-profit organisation. We highly recommend the services of:
Ben Higham, Webhead
Karen Riethmuller, KGR Design
Peter Hersh, Loggica Pty Ltd
Peter Kelso

View all our Acknowledgements

Woolcock Institute
Search Articles
 

First Study of LAM in Mainland China

Clinical analysis of patients with pulmonary lymphangioleiomyomatosis (PLAM) in mainland China

Ye L, Jin M, Bai C.

The Respiratory Dept., Zhongshan Hospital, Fudan University, Shanghai, China.

Abstract

BACKGROUND AND OBJECTIVE: There have been no clinical reports on pulmonary lymphangioleiomyomatosis (PLAM) based on large studies or epidemiological surveys in mainland China. The purpose of this study was to provide a retrospective analysis of PLAM patients in mainland China by reviewing the clinical data of PLAM cases reported.

METHODS: The China Academic Journals Full-text Database search engine was used to collect related cases in mainland China through the end of 2008. 120 cases met the study's inclusion criteria and were reviewed for this analysis.

RESULTS: The average age of the 120 patients upon confirmed diagnosis was 37.3+/-6.4 years. The average duration from onset of symptoms to a confirmed diagnosis was 29.6+/-35.8 months, with 80 person-time patients having experienced misdiagnosis before the confirmed diagnosis. The major clinical manifestations of PLAM included progressive dyspnea, recurrent pneumatothorax, refractory chylothorax. Pulmonary function abnormalities included obstructive pulmonary ventilation disorders and degenerated diffusing capacity. Ten patients were found to be complicated with renal angiomyolipoma and 17 with abdominal or pelvic lymphangioleiomyoma. Half of the patients had undergone antiestrogen therapies such as progesterone, and four patients received pulmonary transplantation. The average duration from the confirmed diagnosis to death was 36.4+/-48.9 months among the 28 cases of death.

CONCLUSIONS: Doctors in mainland China are becoming increasingly vigilant to PLAM, although misdiagnosis or missed diagnosis still exists. Provider attention to the correlation between PLAM and tuberous sclerosis complex, as well as to the possible involvement of multiple organs, is insufficient.